Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ovid Therapeutics Inc OVID

Healthcare Biotechnology
Ovid Therapeutics Inc. is a biopharmaceutical company. The Company is focused on improving the lives of people affected by certain epilepsies and brain conditions with seizure symptoms. It is engaged in advancing a pipeline of novel, targeted small molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of seizures and other... see more

Recent & Breaking News (NDAQ:OVID)

Ovid Therapeutics Provides 2020 Update in Preparation for Multiple Clinical Data Readouts Across Rare Neurological Disease Platform

GlobeNewswire January 7, 2020

Ovid Therapeutics to Participate at the 31st Annual Piper Jaffray Healthcare Conference

GlobeNewswire November 26, 2019

Ovid Therapeutics Appoints Jason Tardio as Chief Commercial Officer

GlobeNewswire November 18, 2019

Ovid Therapeutics Reports Third Quarter 2019 Financial Results and Recent Progress

GlobeNewswire November 8, 2019

Ovid Therapeutics Announces Senior Management Promotions in Preparation for Multiple Data Readouts Expected in 2020

GlobeNewswire November 1, 2019

Ovid Therapeutics Announces Pricing of $32.5 Million of Securities in Concurrent Public Offerings of Common Stock and Preferred Stock

GlobeNewswire October 4, 2019

Ovid Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock

GlobeNewswire October 3, 2019

Ovid Therapeutics Announces Positive Initial Data from Ongoing ENDYMION Open-Label Extension Trial of Soticlestat in People with Rare Epilepsies

GlobeNewswire September 23, 2019

Ovid Therapeutics Announces First Patient Randomized in Pivotal Phase 3 NEPTUNE Trial of OV101 for the Treatment of Angelman Syndrome

GlobeNewswire September 12, 2019

Ovid Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference

GlobeNewswire September 9, 2019

Ovid Therapeutics Announces Participation in Two Upcoming Investor Conferences

GlobeNewswire September 3, 2019

Ovid Therapeutics Reports Second Quarter 2019 Financial Results and Highlights Recent Progress

GlobeNewswire August 7, 2019

Ovid Therapeutics Receives Orphan Drug Designation from the European Commission for OV101 for the Treatment of Angelman Syndrome

Thomson Reuters ONE July 2, 2019

Ovid Therapeutics Receives Orphan Drug Designation from the European Commission for OV101 for the Treatment of Angelman Syndrome

GlobeNewswire July 2, 2019

Ovid Therapeutics Initiates Pivotal Phase 3 Clinical Trial in Angelman Syndrome; Multiple Data Readouts Across Rare Neurological Disease Pipeline Expected in 2H 2019 and Early 2020

GlobeNewswire June 27, 2019

Ovid Therapeutics to Host R&D Day on June 27, 2019

GlobeNewswire June 18, 2019

Ovid Therapeutics to Present at the 12th International Epilepsy Colloquium

PR Newswire May 23, 2019

Ovid Therapeutics Reports First Quarter 2019 Financial Results

GlobeNewswire May 7, 2019

Ovid Therapeutics to Present at the American Academy of Neurology 71st Annual Meeting

GlobeNewswire April 18, 2019

Ovid Therapeutics Announces Senior Management Changes to Align Expertise with Advancing Clinical Stage Pipeline

GlobeNewswire March 28, 2019